生长抑素腹腔灌注治疗癌性腹水的机制研究  

Mechanism of cancerous ascites treated with perfusing somatostatin into abdominal cavity

作　　者：金建军[1] 张世同[1] 张英剑[1] 吴利娟[1] 赵双琴[1] 白艳丽[1] 

机构地区：[1]河南科技大学第一附属医院消化内科,河南洛阳471003

出　　处：《现代肿瘤医学》2011年第11期2260-2262,共3页Journal of Modern Oncology

基　　金：洛阳市科技发展计划项目(编号:051031)

摘　　要：目的:观察生长抑素或者生长抑素联合其它抗癌药腹腔灌注对腹水中VEGF和IL-8含量的影响,从而了解其治疗癌性腹水的机制。方法:把140例癌性腹水患者分为4组,A组:用5氟尿嘧啶(5-FU)+丝裂霉素腹腔灌注;B组:用生长抑素+5-FU+丝裂霉素腹腔灌注;C组:单用生长抑素腹腔灌注;D组:对照组不做腹腔灌注,观察6周。于治疗前和观察结束后,分别检测腹水中血管内皮生长因子(VEGF)和白介素-8(IL-8)的含量。结果:3种治疗方法均可使腹水VEGF和IL-8的含量明显下降,以含生长抑素组下降明显。结论:生长抑素治疗癌性腹水的机理可能和拮抗或抑制VEGF和IL-8的产生有关。Objective：To study mechanism of perfusing somatostatin into abdominal cavity to treat cancerous ascites,through comparing contents variation of VEGF and IL-8 in cancerous ascites before and after treatment.Method： Total of 140 patients with cancerous ascites were divided into 4 groups.Group A：perfused 5-FU ＋Mitomycin into abdominal cavity;Group B：perfused somatostatin ＋5-FU ＋Mitomycin into abdominal cavity;group C：perfused somatostatin into abdominal cavity;group D：control group no perfused.Perfusion treatment for group A,B,C one time every week for 6 weeks.Contents of VEGF and IL-8 in cancerous ascites were detected before and after therapy.Results：The contents of VEGF and IL-8 in cancerous ascites were all reduced in three groups,special in clouding somatostatin groups.Conclusion：Mechanism of perfusing somatostatin into abdominal cavity to treat cancerous ascites concerned with inhibiting and rivalrying creation of of VEGF and IL-8.

关 键 词：癌性腹水 生长抑素腹腔灌注 VEGF IL-8 

分 类 号：R730.6[医药卫生—肿瘤]